Benefits
Kidney Stone Prevention (FDA-Approved)
Potassium citrate is FDA-APPROVED (Urocit-K® prescription) for prevention of calcium oxalate, uric acid, and cystine kidney stones. Mechanism: raises urinary citrate (which inhibits calcium oxalate crystallization) and urinary pH (which prevents uric acid stones). Standard urology care for recurrent stone-formers.
Urinary Alkalinizer
Citrate metabolizes to bicarbonate — raises urinary pH. Used for: gout (uric acid stones), cystinuria (cystine stones), and adjunct in some chemotherapy protocols (urinary alkalinization to reduce kidney damage).
Bone Health (Modest Evidence)
Potassium citrate may modestly support bone health by buffering metabolic acid load (typical Western diets are net-acid-producing). Some evidence for reduced bone resorption markers; effect modest. Whole-diet approach (DASH, Mediterranean) more impactful than single supplement.
Blood Pressure Modest Reduction
Adequate potassium intake reduces blood pressure; potassium citrate provides supplemental potassium without GI ulceration risk of potassium chloride. Modest BP reduction comparable to other potassium sources.
Lower GI Toxicity than Potassium Chloride
Potassium chloride tablets can cause GI ulceration if not adequately diluted. Potassium citrate has less GI toxicity — preferred for patients sensitive to chloride forms or with prior GI issues.
Mechanism of action
Citrate to Bicarbonate Conversion
Absorbed citrate is metabolized in liver to bicarbonate — neutralizes metabolic acid load and raises urinary pH. Urinary citrate excretion increases, providing the stone-prevention mechanism.
Calcium Oxalate Stone Inhibition
Urinary citrate binds calcium and reduces calcium oxalate supersaturation — major mechanism for calcium oxalate stone prevention. Hypocitraturia is a major risk factor for these stones.
Urinary pH Elevation
Raised urinary pH prevents uric acid stone formation (uric acid is more soluble at higher pH) and cystine stone formation. Targeted pH 6.5-7.0 for stone prevention.
Acid-Base Buffering
Bicarbonate generation buffers chronic mild metabolic acidosis from typical Western diets — proposed mechanism for bone-sparing effects.
Clinical trials
Multiple RCTs of potassium citrate (30-60 mEq/day) for prevention of recurrent calcium oxalate kidney stones.
Recurrent calcium oxalate stone-formers.
Potassium citrate significantly reduces recurrent stone formation vs placebo. Standard urology care; recommended in AUA stone prevention guidelines.
Meta-analysis of potassium citrate effects on bone turnover markers and bone density.
Pooled across bone health RCTs.
Potassium citrate modestly reduces bone resorption markers and may slow bone loss. Effect sizes modest. Bone density changes inconsistent across trials. Adjunctive role only.